Tri Locum Partners LP Avadel Pharmaceuticals PLC Transaction History
Tri Locum Partners LP
- $387 Million
- Q2 2024
A detailed history of Tri Locum Partners LP transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, Tri Locum Partners LP holds 1,189,518 shares of AVDL stock, worth $18.4 Million. This represents 4.32% of its overall portfolio holdings.
Number of Shares
1,189,518
Previous 1,189,511
-0.0%
Holding current value
$18.4 Million
Previous $20.1 Million
16.75%
% of portfolio
4.32%
Previous 7.23%
Shares
11 transactions
Others Institutions Holding AVDL
# of Institutions
13Shares Held
7.03MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA3.97MShares$61.4 Million8.25% of portfolio
-
Bio Impact Capital LLC Cambridge, MA783KShares$12.1 Million1.77% of portfolio
-
Knoll Capital Management, LLC Miami, FL600KShares$9.28 Million5.7% of portfolio
-
Knott David M Jr Syosset, NY333KShares$5.15 Million1.87% of portfolio
-
Schulhoff & CO Inc137KShares$2.12 Million0.93% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $937M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...